U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4P
Molecular Weight 94.9714
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -3

SHOW SMILES / InChI
Structure of PHOSPHATE ION

SMILES

[O-]P([O-])([O-])=O

InChI

InChIKey=NBIIXXVUZAFLBC-UHFFFAOYSA-K
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PROCALAMINE
Diagnostic
Palliative
Palliative
Palliative
Primary
SODIUM PHOSPHATES INJECTION
Diagnostic
Palliative
PubMed

PubMed

TitleDatePubMed
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation.
1967 Feb
Determination of inorganic phosphate in serum and saliva using a synthetic receptor.
2003 Jun 12
Amperometric biosensor for determining human salivary phosphate.
2005 Aug 15
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments.
2006 Jun
Patents

Patents

Sample Use Guides

In Vivo Use Guide
lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L). nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration: intravenous; oral
In Vitro Use Guide
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Substance Class Chemical
Created
by admin
on Tue Mar 06 12:09:12 UTC 2018
Edited
by admin
on Tue Mar 06 12:09:12 UTC 2018
Record UNII
NK08V8K8HR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHOSPHATE ION
Common Name English
PHOSPHATE
MART.   VANDF  
Systematic Name English
PHOSPHATE [VANDF]
Common Name English
ORTHOPHOSPHATE
Systematic Name English
PHOSPHATE(3-)
Common Name English
O-PHOSPHATE
Common Name English
PHOSPHATE [MART.]
Common Name English
Code System Code Type Description
PUBCHEM
1061
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY SWITZERF
EPA CompTox
14265-44-2
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY
RXCUI
486961
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY RxNorm
WIKIPEDIA
PHOSPHATE
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY
CAS
14265-44-2
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY
EVMPD
SUB16456MIG
Created by admin on Tue Mar 06 12:09:12 UTC 2018 , Edited by admin on Tue Mar 06 12:09:12 UTC 2018
PRIMARY
Related Record Type Details
ACTIVE MOIETY